Crossmark

Pharmacokinetics of Racemic Eflornithine in Human Plasma and Cerebrospinal Fluid: Clinical Perspectives for L-eflornithine Against Human African Trypanosomiasis

Crossref DOI link: https://doi.org/10.1208/s12248-025-01123-9

Published Online: 2025-09-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Boberg, Mikael https://orcid.org/0000-0002-4422-6226
Na-Bangchang, Kesara

Ashton, Michael https://orcid.org/0000-0001-9122-8294
Jansson-Löfmark, Rasmus https://orcid.org/0000-0003-1773-197X
Funding

Funding for this research was provided by:

University of Gothenburg
License Information

Text and Data Mining valid from 2025-09-04

Version of Record valid from 2025-09-04
More Information

Article History

Received: 5 May 2025

Accepted: 11 August 2025

First Online: 4 September 2025

Declarations

:

: Although authors M.B. and R.J.L. are currently employed by AstraZeneca R&D in Gothenburg, Sweden, AstraZeneca had no influence over the study. The authors declare no competing interests.

Document is current

Any future updates will be listed below